ESSA Pharma Inc has a consensus price target of $18, established from looking at the 6 latest analyst ratings. The last 3 analyst ratings were released from Oppenheimer, Oppenheimer, and Oppenheimer on May 16, 2024, December 13, 2023, and August 9, 2023. With an average price target of $17 between Oppenheimer, Oppenheimer, and Oppenheimer, there's an implied 199.30% upside for ESSA Pharma Inc from these 3 analyst ratings.
1calculated from analyst ratings published within the last 3 years
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
05/16/2024 | Buy Now | 199.3% | Oppenheimer | Leland Gershell | $17 → $17 | Maintains | Outperform | Get Alert |
12/13/2023 | Buy Now | 199.3% | Oppenheimer | Mark Breidenbach | → $17 | Reiterates | Outperform → Outperform | Get Alert |
08/09/2023 | Buy Now | 199.3% | Oppenheimer | Mark Breidenbach | → $17 | Reiterates | Outperform → Outperform | Get Alert |
06/26/2023 | Buy Now | 199.3% | Oppenheimer | Mark Breidenbach | → $17 | Assumes | → Outperform | Get Alert |
05/12/2022 | Buy Now | 252.11% | Piper Sandler | Joseph Catanzaro | $50 → $20 | Maintains | Overweight | Get Alert |
08/17/2021 | Buy Now | 287.32% | Oppenheimer | Mark Breidenbach | — | Maintains | Outperform | Get Alert |
The latest price target for ESSA Pharma (NASDAQ: EPIX) was reported by Oppenheimer on May 16, 2024. The analyst firm set a price target for $17.00 expecting EPIX to rise to within 12 months (a possible 199.30% upside). 4 analyst firms have reported ratings in the last year.
The latest analyst rating for ESSA Pharma (NASDAQ: EPIX) was provided by Oppenheimer, and ESSA Pharma maintained their outperform rating.
There is no last upgrade for ESSA Pharma.
There is no last downgrade for ESSA Pharma.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ESSA Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ESSA Pharma was filed on May 16, 2024 so you should expect the next rating to be made available sometime around May 16, 2025.
While ratings are subjective and will change, the latest ESSA Pharma (EPIX) rating was a maintained with a price target of $17.00 to $17.00. The current price ESSA Pharma (EPIX) is trading at is $5.68, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.